1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
T-cell lymphoma is a rare, diverse subset of hematologic malignancies that challenges clinicians with its therapeutic complexity and substantial unmet needs. Pharmaceutical leaders, healthcare providers, and policy strategists navigating this sector require actionable intelligence to remain competitive across a rapidly evolving global landscape.
Market Snapshot: T-Cell Lymphoma Market Size and Growth
The T-cell lymphoma market expanded from USD 2.25 billion in 2024 to USD 2.35 billion in 2025 and is forecast to maintain a CAGR of 4.08%, reaching USD 2.86 billion by 2030. This consistent trajectory reflects broad advances in therapeutic strategies, robust pipeline development, and the emergence of new approaches to patient management worldwide.
Scope & Segmentation
This report delivers a comprehensive perspective, covering the following market segments and geographies:
- Disease Indications: Cutaneous T-cell lymphoma, mycosis fungoides, Sézary syndrome, extranodal natural killer T-cell lymphoma, anaplastic large-cell lymphoma (ALK negative and ALK positive), angioimmunoblastic T-cell lymphoma, and PTCL not otherwise specified.
- Therapeutic Classes: Chemotherapy, histone deacetylase inhibitors (belinostat, romidepsin), immune checkpoint inhibitors, immunomodulators, and monoclonal antibodies (alemtuzumab, brentuximab vedotin, mogamulizumab).
- Line of Therapy: First-line, second-line, third-line, fourth-line and beyond.
- Patient Types: Adult and pediatric.
- Distribution Channels: Hospital pharmacy, retail pharmacy, specialty pharmacy.
- Regions Covered: Americas (with United States sub-regions), Europe, Middle East & Africa, Asia-Pacific (including China, India, Japan, and more).
- Leading Companies: Seagen Inc., Takeda Pharmaceutical Company Limited, Bristol-Myers Squibb Company, Kyowa Kirin Co., Ltd., Spectrum Pharmaceuticals, Inc., Stemline Therapeutics, Inc., Epizyme, Inc., ADC Therapeutics SA, Merck & Co. Inc.
Key Takeaways for Senior Stakeholders
- Technological innovation, such as immunotherapies and advanced molecular diagnostics, is redefining the therapeutic and diagnostic landscape in T-cell lymphoma and improving the feasibility of patient-centric care models.
- Segmentation by disease subtype and line of therapy reveals actionable differences in patient response, supporting more informed portfolio management, clinical trial design, and go-to-market strategies.
- Collaborative networks across academia, biopharma, and contract research organizations are accelerating trial recruitment and facilitating translational research, enabling the identification of biomarker-driven treatment pathways.
- Integration of digital tools, including mobile applications and remote monitoring, enables real-time data collection and improved individualization of treatment regimens.
- Expansion of regional manufacturing and supply chain partnerships is essential to mitigate external shocks and ensure continued therapy availability, particularly in response to shifting regulatory environments and tariff changes.
Tariff Impact on Market Dynamics
Recent United States tariff adjustments have added new cost pressures on manufacturers, impacting both raw material and finished product imports. Global developers are increasingly deploying localized production strategies and forging alliances with domestic contract manufacturing organizations to protect supply chain resilience and minimize patient disruption. These changes are prompting reallocation of clinical trial investments and driving evolution in value-based payer agreements as stakeholders balance affordability with innovation.
Methodology & Data Sources
This analysis is grounded in primary interviews with key opinion leaders, payer representatives, and patient advocacy groups, synthesized with secondary literature and regulatory filings. A consultative advisory panel validated initial findings, and segmentation utilized standardized frameworks to ensure robust market accuracy.
Why This Report Matters
- This report empowers decision-makers with clarity on competitive positioning, regional opportunities, and the operational impact of regulatory shifts.
- Stakeholders gain precise, actionable insights to inform portfolio development, allocation of clinical trial resources, and optimal go-to-market planning.
Conclusion
T-cell lymphoma therapeutics are advancing due to innovation, segmentation-driven insight, and regional adaptation. Informed, adaptive strategies will be key for leaders aiming to optimize patient reach and commercial performance in this evolving market.
Table of Contents
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Development of CAR T-cell therapies targeting CD30-positive T-cell lymphoma subtypes with durable responses
5.2. Advancements in bispecific antibodies engaging CD3 and tumor antigens to enhance T-cell lymphoma treatment specificity
5.3. Integration of minimal residual disease monitoring in clinical practice to guide personalized T-cell lymphoma therapy decisions
5.4. Expansion of novel epigenetic modifiers as frontline treatment options for patients with relapsed or refractory T-cell lymphoma
5.5. Increasing adoption of next-generation sequencing for molecular profiling to stratify T-cell lymphoma patients by risk profile
5.6. Evaluation of immune checkpoint inhibitors in combination regimens to overcome resistance in peripheral T-cell lymphoma
5.7. Rising interest in oral small molecule inhibitors targeting JAK-STAT pathways for management of T-cell lymphoma symptoms
5.8. Growing clinical focus on translational research exploring microenvironment modulation in T-cell lymphoma disease progression
5.9. Emergence of personalized vaccine strategies leveraging neoantigen identification in therapy-resistant T-cell lymphoma
5.10. Development of real-world evidence platforms to support comparative effectiveness studies in T-cell lymphoma therapies
5.2. Advancements in bispecific antibodies engaging CD3 and tumor antigens to enhance T-cell lymphoma treatment specificity
5.3. Integration of minimal residual disease monitoring in clinical practice to guide personalized T-cell lymphoma therapy decisions
5.4. Expansion of novel epigenetic modifiers as frontline treatment options for patients with relapsed or refractory T-cell lymphoma
5.5. Increasing adoption of next-generation sequencing for molecular profiling to stratify T-cell lymphoma patients by risk profile
5.6. Evaluation of immune checkpoint inhibitors in combination regimens to overcome resistance in peripheral T-cell lymphoma
5.7. Rising interest in oral small molecule inhibitors targeting JAK-STAT pathways for management of T-cell lymphoma symptoms
5.8. Growing clinical focus on translational research exploring microenvironment modulation in T-cell lymphoma disease progression
5.9. Emergence of personalized vaccine strategies leveraging neoantigen identification in therapy-resistant T-cell lymphoma
5.10. Development of real-world evidence platforms to support comparative effectiveness studies in T-cell lymphoma therapies
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
6.2. PESTLE Analysis
8. T-cell lymphoma Market, by Disease Indication
8.1. Introduction
8.2. Cutaneous T-Cell Lymphoma
8.2.1. Mycosis Fungoides
8.2.2. Sézary Syndrome
8.3. Extranodal Natural Killer T-Cell Lymphoma
8.4. Peripheral T-Cell Lymphoma
8.4.1. Anaplastic Large-Cell Lymphoma Alk Negative
8.4.2. Anaplastic Large-Cell Lymphoma Alk Positive
8.4.3. Angioimmunoblastic T-Cell Lymphoma
8.4.4. Ptcl Not Otherwise Specified
8.2. Cutaneous T-Cell Lymphoma
8.2.1. Mycosis Fungoides
8.2.2. Sézary Syndrome
8.3. Extranodal Natural Killer T-Cell Lymphoma
8.4. Peripheral T-Cell Lymphoma
8.4.1. Anaplastic Large-Cell Lymphoma Alk Negative
8.4.2. Anaplastic Large-Cell Lymphoma Alk Positive
8.4.3. Angioimmunoblastic T-Cell Lymphoma
8.4.4. Ptcl Not Otherwise Specified
9. T-cell lymphoma Market, by Therapeutic Class
9.1. Introduction
9.2. Chemotherapy
9.3. Histone Deacetylase Inhibitor
9.3.1. Belinostat
9.3.2. Romidepsin
9.4. Immune Checkpoint Inhibitor
9.5. Immunomodulator
9.6. Monoclonal Antibody
9.6.1. Alemtuzumab
9.6.2. Brentuximab Vedotin
9.6.3. Mogamulizumab
9.2. Chemotherapy
9.3. Histone Deacetylase Inhibitor
9.3.1. Belinostat
9.3.2. Romidepsin
9.4. Immune Checkpoint Inhibitor
9.5. Immunomodulator
9.6. Monoclonal Antibody
9.6.1. Alemtuzumab
9.6.2. Brentuximab Vedotin
9.6.3. Mogamulizumab
10. T-cell lymphoma Market, by Line Of Therapy
10.1. Introduction
10.2. First Line
10.3. Fourth Line And Beyond
10.4. Second Line
10.5. Third Line
10.2. First Line
10.3. Fourth Line And Beyond
10.4. Second Line
10.5. Third Line
11. T-cell lymphoma Market, by Patient Type
11.1. Introduction
11.2. Adult
11.3. Pediatric
11.2. Adult
11.3. Pediatric
12. T-cell lymphoma Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.3. Retail Pharmacy
12.4. Specialty Pharmacy
12.2. Hospital Pharmacy
12.3. Retail Pharmacy
12.4. Specialty Pharmacy
13. Americas T-cell lymphoma Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa T-cell lymphoma Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific T-cell lymphoma Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Seagen Inc.
16.3.2. Takeda Pharmaceutical Company Limited
16.3.3. Bristol-Myers Squibb Company
16.3.4. Kyowa Kirin Co., Ltd.
16.3.5. Spectrum Pharmaceuticals, Inc.
16.3.6. Stemline Therapeutics, Inc.
16.3.7. Epizyme, Inc.
16.3.8. ADC Therapeutics SA
16.3.9. Kyowa Kirin Co., Ltd.
16.3.10. Merck & Co. Inc.
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Seagen Inc.
16.3.2. Takeda Pharmaceutical Company Limited
16.3.3. Bristol-Myers Squibb Company
16.3.4. Kyowa Kirin Co., Ltd.
16.3.5. Spectrum Pharmaceuticals, Inc.
16.3.6. Stemline Therapeutics, Inc.
16.3.7. Epizyme, Inc.
16.3.8. ADC Therapeutics SA
16.3.9. Kyowa Kirin Co., Ltd.
16.3.10. Merck & Co. Inc.
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. T-CELL LYMPHOMA MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL T-CELL LYMPHOMA MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2030 (%)
FIGURE 10. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY PATIENT TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS T-CELL LYMPHOMA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS T-CELL LYMPHOMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES T-CELL LYMPHOMA MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES T-CELL LYMPHOMA MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA T-CELL LYMPHOMA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA T-CELL LYMPHOMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC T-CELL LYMPHOMA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC T-CELL LYMPHOMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. T-CELL LYMPHOMA MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. T-CELL LYMPHOMA MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. T-CELL LYMPHOMA MARKET: RESEARCHAI
FIGURE 26. T-CELL LYMPHOMA MARKET: RESEARCHSTATISTICS
FIGURE 27. T-CELL LYMPHOMA MARKET: RESEARCHCONTACTS
FIGURE 28. T-CELL LYMPHOMA MARKET: RESEARCHARTICLES
FIGURE 2. GLOBAL T-CELL LYMPHOMA MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2030 (%)
FIGURE 10. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY PATIENT TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS T-CELL LYMPHOMA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS T-CELL LYMPHOMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES T-CELL LYMPHOMA MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES T-CELL LYMPHOMA MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA T-CELL LYMPHOMA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA T-CELL LYMPHOMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC T-CELL LYMPHOMA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC T-CELL LYMPHOMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. T-CELL LYMPHOMA MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. T-CELL LYMPHOMA MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. T-CELL LYMPHOMA MARKET: RESEARCHAI
FIGURE 26. T-CELL LYMPHOMA MARKET: RESEARCHSTATISTICS
FIGURE 27. T-CELL LYMPHOMA MARKET: RESEARCHCONTACTS
FIGURE 28. T-CELL LYMPHOMA MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. T-CELL LYMPHOMA MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL T-CELL LYMPHOMA MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL T-CELL LYMPHOMA MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY MYCOSIS FUNGOIDES, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY MYCOSIS FUNGOIDES, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY SÉZARY SYNDROME, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY SÉZARY SYNDROME, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY EXTRANODAL NATURAL KILLER T-CELL LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY EXTRANODAL NATURAL KILLER T-CELL LYMPHOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY ANAPLASTIC LARGE-CELL LYMPHOMA ALK NEGATIVE, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY ANAPLASTIC LARGE-CELL LYMPHOMA ALK NEGATIVE, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY ANAPLASTIC LARGE-CELL LYMPHOMA ALK POSITIVE, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY ANAPLASTIC LARGE-CELL LYMPHOMA ALK POSITIVE, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY PTCL NOT OTHERWISE SPECIFIED, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY PTCL NOT OTHERWISE SPECIFIED, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY BELINOSTAT, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY BELINOSTAT, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY ROMIDEPSIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY ROMIDEPSIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY IMMUNOMODULATOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY IMMUNOMODULATOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY ALEMTUZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY ALEMTUZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY BRENTUXIMAB VEDOTIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY BRENTUXIMAB VEDOTIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY MOGAMULIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY MOGAMULIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY MONOCLONAL ANTIBODY, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY FOURTH LINE AND BEYOND, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY FOURTH LINE AND BEYOND, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY THIRD LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS T-CELL LYMPHOMA MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS T-CELL LYMPHOMA MARKET SIZE, BY DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS T-CELL LYMPHOMA MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS T-CELL LYMPHOMA MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS T-CELL LYMPHOMA MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS T-CELL LYMPHOMA MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS T-CELL LYMPHOMA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS T-CELL LYMPHOMA MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS T-CELL LYMPHOMA MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS T-CELL LYMPHOMA MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS T-CELL LYMPHOMA MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS T-CELL LYMPHOMA MARKET SIZE, BY MONOCLONAL ANTIBODY, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS T-CELL LYMPHOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS T-CELL LYMPHOMA MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS T-CELL LYMPHOMA MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS T-CELL LYMPHOMA MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS T-CELL LYMPHOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS T-CELL LYMPHOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS T-CELL LYMPHOMA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS T-CELL LYMPHOMA MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES T-CELL LYMPHOMA MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES T-CELL LYMPHOMA MARKET SIZE, BY DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES T-CELL LYMPHOMA MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES T-CELL LYMPHOMA MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES T-CELL LYMPHOMA MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES T-CELL LYMPHOMA MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES T-CELL LYMPHOMA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES T-CELL LYMPHOMA MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES T-CELL LYMPHOMA MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES T-CELL LYMPHOMA MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES T-CELL LYMPHOMA MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES T-CELL LYMPHOMA MARKET SIZE, BY MONOCLONAL ANTIBODY, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES T-CELL LYMPHOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES T-CELL LYMPHOMA MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES T-CELL LYMPHOMA MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES T-CELL LYMPHOMA MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES T-CELL LYMPHOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES T-CELL LYMPHOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES T-CELL LYMPHOMA MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES T-CELL LYMPHOMA MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 123. CANADA T-CELL LYMPHOMA MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 124. CANADA T-CELL LYMPHOMA MARKET SIZE, BY DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 125. CANADA T-CELL LYMPHOMA MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 126. CANADA T-CELL LYMPHOMA MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 127. CANADA T-CELL LYMPHOMA MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 128. CANADA T-CELL LYMPHOMA MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 129. CANADA T-CELL LYMPHOMA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 130. CANADA T-CELL LYMPHOMA MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 131. CANADA T-CELL LYMPHOMA MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 132. CANADA T-CELL LYMPHOMA MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 133. CANADA T-CELL LYMPHOMA MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2024 (USD MILLION)
TABLE 134. CANADA T-CELL LYMPHOMA MARKET SIZE, BY MONOCLONAL ANTIBODY, 2025-2030 (USD MILLION)
TABLE 135. CANADA T-CELL LYMPHOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 136. CANADA T-CELL LYMPHOMA MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 137. CANADA T-CELL LYMPHOMA MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 138. CANADA T-CELL LYMPHOMA MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 139. CANADA T-CELL LYMPHOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 140. CANADA T-CELL LYMPHOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 141. MEXICO T-CELL LYMPHOMA MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 142. MEXICO T-CELL LYMPHOMA MARKET SIZE, BY DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 143. MEXICO T-CELL LYMPHOMA MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 144. MEXICO T-CELL LYMPHOMA MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 145. MEXICO T-CELL LYMPHOMA MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 146. MEXICO T-CELL LYMPHOMA MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 147. MEXICO T-CELL LYMPHOMA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 148. MEXICO T-CELL LYMPHOMA MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 149. MEXICO T-CELL LYMPHOMA MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 150. MEXICO T-CELL LYMPHOMA MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 151. MEXICO T-CELL LYMPHOMA MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2024 (USD MILLION)
TABLE 152. MEXICO T-CELL LYMPHOMA MARKET SIZE, BY MONOCLONAL ANTIBODY, 2025-2030 (USD MILLION)
TABLE 153. MEXICO T-CELL LYMPHOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 154. MEXICO T-CELL LYMPHOMA MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 155. MEXICO T-CELL LYMPHOMA MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 156. MEXICO T-CELL LYMPHOMA MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 157. MEXICO T-CELL LYMPHOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 158. MEXICO T-CELL LYMPHOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 159. BRAZIL T-CELL LYMPHOMA MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 160. BRAZIL T-CELL LYMPHOMA MARKET SIZE, BY DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 161. BRAZIL T-CELL LYMPHOMA MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 162. BRAZIL T-CELL LYMPHOMA MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 163. BRAZIL T-CELL LYMPHOMA MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 164. BRAZIL T-CELL LYMPHOMA MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 165. BRAZIL T-CELL LYMPHOMA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 166. BRAZIL T-CELL LYMPHOMA MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 167. BRAZIL T-CELL LYMPHOMA MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 168. BRAZIL T-CELL LYMPHOMA MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 169. BRAZIL T-CELL LYMPHOMA MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2024 (USD MILLION)
TABLE 170. BRAZIL T-CELL LYMPHOMA MARKET SIZE, BY MONOCLONAL ANTIBODY, 2025-2030 (USD MILLION)
TABLE 171. BRAZIL T-CELL LYMPHOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 172. BRAZIL T-CELL LYMPHOMA MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 173. BRAZIL T-CELL LYMPHOMA MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 174. BRAZIL T-CELL LYMPHOMA MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 175. BRAZIL T-CELL LYMPHOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 176. BRAZIL T-CELL LYMPHOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 177. ARGENTINA T-CELL LYMPHOMA MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 178. ARGENTINA T-CELL LYMPHOMA MARKET SIZE, BY DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 179. ARGENTINA T-CELL LYMPHOMA MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 180. ARGENTINA T-CELL LYMPHOMA MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 181. ARGENTINA T-CELL LYMPHOMA MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 182. ARGENTINA T-CELL LYMPHOMA MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 183. ARGENTINA T-CELL LYMPHOMA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 184. ARGENTINA T-CELL LYMPHOMA MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 185. ARGENTINA T-CELL LYMPHOMA MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 186. ARGENTINA T-CELL LYMPHOMA MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 187. ARGENTINA T-CELL LYMPHOMA MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2024 (USD MILLION)
TABLE 188. ARGENTINA T-CELL LYMPHOMA MARKET SIZE, BY MONOCLONAL ANTIBODY, 2025-2030 (USD MILLION)
TABLE 189. ARGENTINA T-CELL LYMPHOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 190. ARGENTINA T-CELL LYMPHOMA MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 191. ARGENTINA T-CELL LYMPHOMA MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 192. ARGENTINA T-CELL LYMPHOMA MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 193. ARGENTINA T-CELL LYMPHOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 194. ARGENTINA T-CELL LYMPHOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA T-CELL LYMPHOMA MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA T-CELL LYMPHOMA MARKET SIZE, BY DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA T-CELL LYMPHOMA MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA T-CELL LYMPHOMA MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA T-CELL LYMPHOMA MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA T-CELL LYMPHOMA MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA T-CELL LYMPHOMA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA T-CELL LYMPHOMA MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA T-CELL LYMPHOMA MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA T-CELL LYMPHOMA MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 205. EUROPE, MIDDLE EAST & AFRICA T-CELL LYMPHOMA MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2024 (USD MILLION)
TABLE 206. EUROPE, MIDDLE EAST & AFRICA T-CELL LYMPHOMA MARKET SIZE, BY MONOCLONAL ANTIBODY, 2025-2030 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA T-CELL LYMPHOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA T-CELL LYMPHOMA MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 209. EUROPE, MIDDLE EAST & AFRICA T-CELL LYMPHOMA MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA T-CELL LYMPHOMA MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 211. EUROPE, MIDDLE EAST & AFRICA T-CELL LYMPHOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 212. EUROPE, MIDDLE EAST & AFRICA T-CELL LYMPHOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 213. EUROPE, MIDDLE EAST & AFRICA T-CELL LYMPHOMA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 214. EUROPE, MIDDLE EAST & AFRICA T-CELL LYMPHOMA MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 215. UNITED KINGDOM T-CELL LYMPHOMA MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 216. UNITED KINGDOM T-CELL LYMPHOMA MARKET SIZE, BY DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 217. UNITED KINGDOM T-CELL LYMPHOMA MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 218. UNITED KINGDOM T-CELL LYMPHOMA MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 219. UNITED KINGDOM T-CELL LYMPHOMA MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 220. UNITED KINGDOM T-CELL LYMPHOMA MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 221. UNITED KINGDOM T-CELL LYMPHOMA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 222. UNITED KINGDOM T-CELL LYMPHOMA MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 223. UNITED KINGDOM T-CELL LYMPHOMA MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 224. UNITED KINGDOM T-CELL LYMPHOMA MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 225. UNITED KINGDOM T-CELL LYMPHOMA MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2024 (USD MILLION)
TABLE 226. UNITED KINGDOM T-CELL LYMPHOMA MARKET SIZE, BY MONOCLONAL ANTIBODY, 2025-2030 (USD MILLION)
TABLE 227. UNITED KINGDOM T-CELL LYMPHOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 228. UNITED KINGDOM T-CELL LYMPHOMA MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 229. UNITED KINGDOM T-CELL LYMPHOMA MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 230. UNITED KINGDOM T-CELL LYMPHOMA MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 231. UNITED KINGDOM T-CELL LYMPHOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 232. UNITED KINGDOM T-CELL LYMPHOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 233. GERMANY T-CELL LYMPHOMA MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 234. GERMANY T-CELL LYMPHOMA MARKET SIZE, BY DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 235. GERMANY T-CELL LYMPHOMA MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 236. GERMANY T-CELL LYMPHOMA MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 237. GERMANY T-CELL LYMPHOMA MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 238. GERMANY T-CELL LYMPHOMA MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 239. GERMANY T-CELL LYMPHOMA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 240. GERMANY T-CELL LYMPHOMA MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 241. GERMANY T-CELL LYMPHOMA MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 242. GERMANY T-CELL LYMPHOMA MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 243. GERMANY T-CELL LYMPHOMA MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2024 (USD MILLION)
TABLE 244. GERMANY T-CELL LYMPHOMA MARKET SIZE, BY MONOCLONAL ANTIBODY, 2025-2030 (USD MILLION)
TABLE 245. GERMANY T-CELL LYMPHOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 246. GERMANY T-CELL LYMPHOMA MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 247. GERMANY T-CELL LYMPHOMA MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 248. GERMANY T-CELL LYMPHOMA MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 249. GERMANY T-CELL LYMPHOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 250. GERMANY T-CELL LYMPHOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 251. FRANCE T-CELL LYMPHOMA MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 252. FRANCE T-CELL LYMPHOMA MARKET SIZE, BY DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 253. FRANCE T-CELL LYMPHOMA MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 254. FRANCE T-CELL LYMPHOMA MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 255. FRANCE T-CELL LYMPHOMA MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 256. FRANCE T-CELL LYMPHOMA MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 257. FRANCE T-CELL LYMPHOMA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 258. FRANCE T-CELL LYMPHOMA MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 259. FRANCE T-CELL LYMPHOMA MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 260. FRANCE T-CELL LYMPHOMA MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 261. FRANCE T-CELL LYMPHOMA MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2024 (USD MILLION)
TABLE 262. FRANCE T-CELL LYMPHOMA MARKET SIZE, BY MONOCLONAL ANTIBODY, 2025-2030 (USD MILLION)
TABLE 263. FRANCE T-CELL LYMPHOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 264. FRANCE T-CELL LYMPHOMA MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 265. FRANCE T-CELL LYMPHOMA MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 266. FRANCE T-CELL LYMPHOMA MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 267. FRANCE T-CELL LYMPHOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 268. FRANCE T-CELL LYMPHOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 269. RUSSIA T-CELL LYMPHOMA MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 270. RUSSIA T-CELL LYMPHOMA MARKET SIZE, BY DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 271. RUSSIA T-CELL LYMPHOMA MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 272. RUSSIA T-CELL LYMPHOMA MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 273. RUSSIA T-CELL LYMPHOMA MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 274. RUSSIA T-CELL LYMPHOMA MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 275. RUSSIA T-CELL LYMPHOMA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 276. RUSSIA T-CELL LYMPHOMA MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 277. RUSSIA T-CELL LYMPHOMA MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 278. RUSSIA T-CELL LYMPHOMA MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 279. RUSSIA T-CELL LYMPHOMA MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2024 (USD MILLION)
TABLE 280. RUSSIA T-CELL LYMPHOMA MARKET SIZE, BY MONOCLONAL ANTIBODY, 2025-2030 (USD MILLION)
TABLE 281. RUSSIA T-CELL LYMPHOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 282. RUSSIA T-CELL LYMPHOMA MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 283. RUSSIA T-CELL LYMPHOMA MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 284. RUSSIA T-CELL LYMPHOMA MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 285. RUSSIA T-CELL LYMPHOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 286. RUSSIA T-CELL LYMPHOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 287. ITALY T-CELL LYMPHOMA MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 288. ITALY T-CELL LYMPHOMA MARKET SIZE, BY DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 289. ITALY T-CELL LYMPHOMA MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 290. ITALY T-CELL LYMPHOMA MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 291. ITALY T-CELL LYMPHOMA MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 292. ITALY T-CELL LYMPHOMA MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 293. ITALY T-CELL LYMPHOMA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 294. ITALY T-CELL LYMPHOMA MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 295. ITALY T-CELL LYMPHOMA MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 296. ITALY T-CELL LYMPHOMA MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 297. ITALY T-CELL LYMPHOMA MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2024 (USD MILLION)
TABLE 298. ITALY T-CELL LYMPHOMA MARKET SIZE, BY MONOCLONAL ANTIBODY, 2025-2030 (USD MILLION)
TABLE 299. ITALY T-CELL LYMPHOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 300. ITALY T-CELL LYMPHOMA MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 301. ITALY T-CELL LYMPHOMA MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 302. ITALY T-CELL LYMPHOMA MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 303. ITALY T-CELL LYMPHOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 304. ITALY T-CELL LYMPHOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 305. SPAIN T-CELL LYMPHOMA MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 306. SPAIN T-CELL LYMPHOMA MARKET SIZE, BY DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 307. SPAIN T-CELL LYMPHOMA MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 308. SPAIN T-CELL LYMPHOMA MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 309. SPAIN T-CELL LYMPHOMA MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 310. SPAIN T-CELL LYMPHOMA MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 311. SPAIN T-CELL LYMPHOMA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 312. SPAIN T-CELL LYMPHOMA MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 313. SPAIN T-CELL LYMPHOMA MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 314. SPAIN T-CELL LYMPHOMA MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 315. SPAIN T-CELL LYMPHOMA MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2024 (USD MILLION)
TABLE 316. SPAIN T-CELL LYMPHOMA MARKET SIZE, BY MONOCLONAL ANTIBODY, 2025-2030 (USD MILLION)
TABLE 317. SPAIN T-CELL LYMPHOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 318. SPAIN T-CELL LYMPHOMA MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 319. SPAIN T-CELL LYMPHOMA MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 320. SPAIN T-CELL LYMPHOMA MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 321. SPAIN T-CELL LYMPHOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 322. SPAIN T-CELL LYMPHOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 323. UNITED ARAB EMIRATES T-CELL LYMPHOMA MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 324. UNITED ARAB EMIRATES T-CELL LYMPHOMA MARKET SIZE, BY DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 325. UNITED ARAB EMIRATES T-CELL LYMPHOMA MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 326. UNITED ARAB EMIRATES T-CELL LYMPHOMA MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 327. UNITED ARAB EMIRATES T-CELL LYMPHOMA MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 328. UNITED ARAB EMIRATES T-CELL LYMPHOMA MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 329. UNITED ARAB EMIRATES T-CELL LYMPHOMA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 3
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL T-CELL LYMPHOMA MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL T-CELL LYMPHOMA MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY MYCOSIS FUNGOIDES, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY MYCOSIS FUNGOIDES, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY SÉZARY SYNDROME, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY SÉZARY SYNDROME, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY EXTRANODAL NATURAL KILLER T-CELL LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY EXTRANODAL NATURAL KILLER T-CELL LYMPHOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY ANAPLASTIC LARGE-CELL LYMPHOMA ALK NEGATIVE, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY ANAPLASTIC LARGE-CELL LYMPHOMA ALK NEGATIVE, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY ANAPLASTIC LARGE-CELL LYMPHOMA ALK POSITIVE, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY ANAPLASTIC LARGE-CELL LYMPHOMA ALK POSITIVE, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY PTCL NOT OTHERWISE SPECIFIED, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY PTCL NOT OTHERWISE SPECIFIED, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY BELINOSTAT, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY BELINOSTAT, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY ROMIDEPSIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY ROMIDEPSIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY IMMUNOMODULATOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY IMMUNOMODULATOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY ALEMTUZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY ALEMTUZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY BRENTUXIMAB VEDOTIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY BRENTUXIMAB VEDOTIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY MOGAMULIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY MOGAMULIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY MONOCLONAL ANTIBODY, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY FOURTH LINE AND BEYOND, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY FOURTH LINE AND BEYOND, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY THIRD LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS T-CELL LYMPHOMA MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS T-CELL LYMPHOMA MARKET SIZE, BY DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS T-CELL LYMPHOMA MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS T-CELL LYMPHOMA MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS T-CELL LYMPHOMA MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS T-CELL LYMPHOMA MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS T-CELL LYMPHOMA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS T-CELL LYMPHOMA MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS T-CELL LYMPHOMA MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS T-CELL LYMPHOMA MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS T-CELL LYMPHOMA MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS T-CELL LYMPHOMA MARKET SIZE, BY MONOCLONAL ANTIBODY, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS T-CELL LYMPHOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS T-CELL LYMPHOMA MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS T-CELL LYMPHOMA MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS T-CELL LYMPHOMA MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS T-CELL LYMPHOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS T-CELL LYMPHOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS T-CELL LYMPHOMA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS T-CELL LYMPHOMA MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES T-CELL LYMPHOMA MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES T-CELL LYMPHOMA MARKET SIZE, BY DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES T-CELL LYMPHOMA MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES T-CELL LYMPHOMA MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES T-CELL LYMPHOMA MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES T-CELL LYMPHOMA MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES T-CELL LYMPHOMA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES T-CELL LYMPHOMA MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES T-CELL LYMPHOMA MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES T-CELL LYMPHOMA MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES T-CELL LYMPHOMA MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES T-CELL LYMPHOMA MARKET SIZE, BY MONOCLONAL ANTIBODY, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES T-CELL LYMPHOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES T-CELL LYMPHOMA MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES T-CELL LYMPHOMA MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES T-CELL LYMPHOMA MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES T-CELL LYMPHOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES T-CELL LYMPHOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES T-CELL LYMPHOMA MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES T-CELL LYMPHOMA MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 123. CANADA T-CELL LYMPHOMA MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 124. CANADA T-CELL LYMPHOMA MARKET SIZE, BY DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 125. CANADA T-CELL LYMPHOMA MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 126. CANADA T-CELL LYMPHOMA MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 127. CANADA T-CELL LYMPHOMA MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 128. CANADA T-CELL LYMPHOMA MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 129. CANADA T-CELL LYMPHOMA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 130. CANADA T-CELL LYMPHOMA MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 131. CANADA T-CELL LYMPHOMA MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 132. CANADA T-CELL LYMPHOMA MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 133. CANADA T-CELL LYMPHOMA MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2024 (USD MILLION)
TABLE 134. CANADA T-CELL LYMPHOMA MARKET SIZE, BY MONOCLONAL ANTIBODY, 2025-2030 (USD MILLION)
TABLE 135. CANADA T-CELL LYMPHOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 136. CANADA T-CELL LYMPHOMA MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 137. CANADA T-CELL LYMPHOMA MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 138. CANADA T-CELL LYMPHOMA MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 139. CANADA T-CELL LYMPHOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 140. CANADA T-CELL LYMPHOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 141. MEXICO T-CELL LYMPHOMA MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 142. MEXICO T-CELL LYMPHOMA MARKET SIZE, BY DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 143. MEXICO T-CELL LYMPHOMA MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 144. MEXICO T-CELL LYMPHOMA MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 145. MEXICO T-CELL LYMPHOMA MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 146. MEXICO T-CELL LYMPHOMA MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 147. MEXICO T-CELL LYMPHOMA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 148. MEXICO T-CELL LYMPHOMA MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 149. MEXICO T-CELL LYMPHOMA MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 150. MEXICO T-CELL LYMPHOMA MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 151. MEXICO T-CELL LYMPHOMA MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2024 (USD MILLION)
TABLE 152. MEXICO T-CELL LYMPHOMA MARKET SIZE, BY MONOCLONAL ANTIBODY, 2025-2030 (USD MILLION)
TABLE 153. MEXICO T-CELL LYMPHOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 154. MEXICO T-CELL LYMPHOMA MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 155. MEXICO T-CELL LYMPHOMA MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 156. MEXICO T-CELL LYMPHOMA MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 157. MEXICO T-CELL LYMPHOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 158. MEXICO T-CELL LYMPHOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 159. BRAZIL T-CELL LYMPHOMA MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 160. BRAZIL T-CELL LYMPHOMA MARKET SIZE, BY DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 161. BRAZIL T-CELL LYMPHOMA MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 162. BRAZIL T-CELL LYMPHOMA MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 163. BRAZIL T-CELL LYMPHOMA MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 164. BRAZIL T-CELL LYMPHOMA MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 165. BRAZIL T-CELL LYMPHOMA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 166. BRAZIL T-CELL LYMPHOMA MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 167. BRAZIL T-CELL LYMPHOMA MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 168. BRAZIL T-CELL LYMPHOMA MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 169. BRAZIL T-CELL LYMPHOMA MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2024 (USD MILLION)
TABLE 170. BRAZIL T-CELL LYMPHOMA MARKET SIZE, BY MONOCLONAL ANTIBODY, 2025-2030 (USD MILLION)
TABLE 171. BRAZIL T-CELL LYMPHOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 172. BRAZIL T-CELL LYMPHOMA MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 173. BRAZIL T-CELL LYMPHOMA MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 174. BRAZIL T-CELL LYMPHOMA MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 175. BRAZIL T-CELL LYMPHOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 176. BRAZIL T-CELL LYMPHOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 177. ARGENTINA T-CELL LYMPHOMA MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 178. ARGENTINA T-CELL LYMPHOMA MARKET SIZE, BY DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 179. ARGENTINA T-CELL LYMPHOMA MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 180. ARGENTINA T-CELL LYMPHOMA MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 181. ARGENTINA T-CELL LYMPHOMA MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 182. ARGENTINA T-CELL LYMPHOMA MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 183. ARGENTINA T-CELL LYMPHOMA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 184. ARGENTINA T-CELL LYMPHOMA MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 185. ARGENTINA T-CELL LYMPHOMA MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 186. ARGENTINA T-CELL LYMPHOMA MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 187. ARGENTINA T-CELL LYMPHOMA MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2024 (USD MILLION)
TABLE 188. ARGENTINA T-CELL LYMPHOMA MARKET SIZE, BY MONOCLONAL ANTIBODY, 2025-2030 (USD MILLION)
TABLE 189. ARGENTINA T-CELL LYMPHOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 190. ARGENTINA T-CELL LYMPHOMA MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 191. ARGENTINA T-CELL LYMPHOMA MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 192. ARGENTINA T-CELL LYMPHOMA MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 193. ARGENTINA T-CELL LYMPHOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 194. ARGENTINA T-CELL LYMPHOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA T-CELL LYMPHOMA MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA T-CELL LYMPHOMA MARKET SIZE, BY DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA T-CELL LYMPHOMA MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA T-CELL LYMPHOMA MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA T-CELL LYMPHOMA MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA T-CELL LYMPHOMA MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA T-CELL LYMPHOMA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA T-CELL LYMPHOMA MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA T-CELL LYMPHOMA MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA T-CELL LYMPHOMA MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 205. EUROPE, MIDDLE EAST & AFRICA T-CELL LYMPHOMA MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2024 (USD MILLION)
TABLE 206. EUROPE, MIDDLE EAST & AFRICA T-CELL LYMPHOMA MARKET SIZE, BY MONOCLONAL ANTIBODY, 2025-2030 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA T-CELL LYMPHOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA T-CELL LYMPHOMA MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 209. EUROPE, MIDDLE EAST & AFRICA T-CELL LYMPHOMA MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA T-CELL LYMPHOMA MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 211. EUROPE, MIDDLE EAST & AFRICA T-CELL LYMPHOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 212. EUROPE, MIDDLE EAST & AFRICA T-CELL LYMPHOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 213. EUROPE, MIDDLE EAST & AFRICA T-CELL LYMPHOMA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 214. EUROPE, MIDDLE EAST & AFRICA T-CELL LYMPHOMA MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 215. UNITED KINGDOM T-CELL LYMPHOMA MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 216. UNITED KINGDOM T-CELL LYMPHOMA MARKET SIZE, BY DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 217. UNITED KINGDOM T-CELL LYMPHOMA MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 218. UNITED KINGDOM T-CELL LYMPHOMA MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 219. UNITED KINGDOM T-CELL LYMPHOMA MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 220. UNITED KINGDOM T-CELL LYMPHOMA MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 221. UNITED KINGDOM T-CELL LYMPHOMA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 222. UNITED KINGDOM T-CELL LYMPHOMA MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 223. UNITED KINGDOM T-CELL LYMPHOMA MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 224. UNITED KINGDOM T-CELL LYMPHOMA MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 225. UNITED KINGDOM T-CELL LYMPHOMA MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2024 (USD MILLION)
TABLE 226. UNITED KINGDOM T-CELL LYMPHOMA MARKET SIZE, BY MONOCLONAL ANTIBODY, 2025-2030 (USD MILLION)
TABLE 227. UNITED KINGDOM T-CELL LYMPHOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 228. UNITED KINGDOM T-CELL LYMPHOMA MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 229. UNITED KINGDOM T-CELL LYMPHOMA MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 230. UNITED KINGDOM T-CELL LYMPHOMA MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 231. UNITED KINGDOM T-CELL LYMPHOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 232. UNITED KINGDOM T-CELL LYMPHOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 233. GERMANY T-CELL LYMPHOMA MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 234. GERMANY T-CELL LYMPHOMA MARKET SIZE, BY DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 235. GERMANY T-CELL LYMPHOMA MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 236. GERMANY T-CELL LYMPHOMA MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 237. GERMANY T-CELL LYMPHOMA MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 238. GERMANY T-CELL LYMPHOMA MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 239. GERMANY T-CELL LYMPHOMA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 240. GERMANY T-CELL LYMPHOMA MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 241. GERMANY T-CELL LYMPHOMA MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 242. GERMANY T-CELL LYMPHOMA MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 243. GERMANY T-CELL LYMPHOMA MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2024 (USD MILLION)
TABLE 244. GERMANY T-CELL LYMPHOMA MARKET SIZE, BY MONOCLONAL ANTIBODY, 2025-2030 (USD MILLION)
TABLE 245. GERMANY T-CELL LYMPHOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 246. GERMANY T-CELL LYMPHOMA MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 247. GERMANY T-CELL LYMPHOMA MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 248. GERMANY T-CELL LYMPHOMA MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 249. GERMANY T-CELL LYMPHOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 250. GERMANY T-CELL LYMPHOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 251. FRANCE T-CELL LYMPHOMA MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 252. FRANCE T-CELL LYMPHOMA MARKET SIZE, BY DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 253. FRANCE T-CELL LYMPHOMA MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 254. FRANCE T-CELL LYMPHOMA MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 255. FRANCE T-CELL LYMPHOMA MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 256. FRANCE T-CELL LYMPHOMA MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 257. FRANCE T-CELL LYMPHOMA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 258. FRANCE T-CELL LYMPHOMA MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 259. FRANCE T-CELL LYMPHOMA MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 260. FRANCE T-CELL LYMPHOMA MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 261. FRANCE T-CELL LYMPHOMA MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2024 (USD MILLION)
TABLE 262. FRANCE T-CELL LYMPHOMA MARKET SIZE, BY MONOCLONAL ANTIBODY, 2025-2030 (USD MILLION)
TABLE 263. FRANCE T-CELL LYMPHOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 264. FRANCE T-CELL LYMPHOMA MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 265. FRANCE T-CELL LYMPHOMA MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 266. FRANCE T-CELL LYMPHOMA MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 267. FRANCE T-CELL LYMPHOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 268. FRANCE T-CELL LYMPHOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 269. RUSSIA T-CELL LYMPHOMA MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 270. RUSSIA T-CELL LYMPHOMA MARKET SIZE, BY DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 271. RUSSIA T-CELL LYMPHOMA MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 272. RUSSIA T-CELL LYMPHOMA MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 273. RUSSIA T-CELL LYMPHOMA MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 274. RUSSIA T-CELL LYMPHOMA MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 275. RUSSIA T-CELL LYMPHOMA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 276. RUSSIA T-CELL LYMPHOMA MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 277. RUSSIA T-CELL LYMPHOMA MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 278. RUSSIA T-CELL LYMPHOMA MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 279. RUSSIA T-CELL LYMPHOMA MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2024 (USD MILLION)
TABLE 280. RUSSIA T-CELL LYMPHOMA MARKET SIZE, BY MONOCLONAL ANTIBODY, 2025-2030 (USD MILLION)
TABLE 281. RUSSIA T-CELL LYMPHOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 282. RUSSIA T-CELL LYMPHOMA MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 283. RUSSIA T-CELL LYMPHOMA MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 284. RUSSIA T-CELL LYMPHOMA MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 285. RUSSIA T-CELL LYMPHOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 286. RUSSIA T-CELL LYMPHOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 287. ITALY T-CELL LYMPHOMA MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 288. ITALY T-CELL LYMPHOMA MARKET SIZE, BY DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 289. ITALY T-CELL LYMPHOMA MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 290. ITALY T-CELL LYMPHOMA MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 291. ITALY T-CELL LYMPHOMA MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 292. ITALY T-CELL LYMPHOMA MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 293. ITALY T-CELL LYMPHOMA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 294. ITALY T-CELL LYMPHOMA MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 295. ITALY T-CELL LYMPHOMA MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 296. ITALY T-CELL LYMPHOMA MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 297. ITALY T-CELL LYMPHOMA MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2024 (USD MILLION)
TABLE 298. ITALY T-CELL LYMPHOMA MARKET SIZE, BY MONOCLONAL ANTIBODY, 2025-2030 (USD MILLION)
TABLE 299. ITALY T-CELL LYMPHOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 300. ITALY T-CELL LYMPHOMA MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 301. ITALY T-CELL LYMPHOMA MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 302. ITALY T-CELL LYMPHOMA MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 303. ITALY T-CELL LYMPHOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 304. ITALY T-CELL LYMPHOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 305. SPAIN T-CELL LYMPHOMA MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 306. SPAIN T-CELL LYMPHOMA MARKET SIZE, BY DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 307. SPAIN T-CELL LYMPHOMA MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 308. SPAIN T-CELL LYMPHOMA MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 309. SPAIN T-CELL LYMPHOMA MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 310. SPAIN T-CELL LYMPHOMA MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 311. SPAIN T-CELL LYMPHOMA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 312. SPAIN T-CELL LYMPHOMA MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 313. SPAIN T-CELL LYMPHOMA MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 314. SPAIN T-CELL LYMPHOMA MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 315. SPAIN T-CELL LYMPHOMA MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2024 (USD MILLION)
TABLE 316. SPAIN T-CELL LYMPHOMA MARKET SIZE, BY MONOCLONAL ANTIBODY, 2025-2030 (USD MILLION)
TABLE 317. SPAIN T-CELL LYMPHOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 318. SPAIN T-CELL LYMPHOMA MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 319. SPAIN T-CELL LYMPHOMA MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 320. SPAIN T-CELL LYMPHOMA MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 321. SPAIN T-CELL LYMPHOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 322. SPAIN T-CELL LYMPHOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 323. UNITED ARAB EMIRATES T-CELL LYMPHOMA MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 324. UNITED ARAB EMIRATES T-CELL LYMPHOMA MARKET SIZE, BY DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 325. UNITED ARAB EMIRATES T-CELL LYMPHOMA MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 326. UNITED ARAB EMIRATES T-CELL LYMPHOMA MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 327. UNITED ARAB EMIRATES T-CELL LYMPHOMA MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 328. UNITED ARAB EMIRATES T-CELL LYMPHOMA MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 329. UNITED ARAB EMIRATES T-CELL LYMPHOMA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 3
Samples
LOADING...
Companies Mentioned
The companies profiled in this T-cell lymphoma market report include:- Seagen Inc.
- Takeda Pharmaceutical Company Limited
- Bristol-Myers Squibb Company
- Kyowa Kirin Co., Ltd.
- Spectrum Pharmaceuticals, Inc.
- Stemline Therapeutics, Inc.
- Epizyme, Inc.
- ADC Therapeutics SA
- Kyowa Kirin Co., Ltd.
- Merck & Co. Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 196 |
| Published | August 2025 |
| Forecast Period | 2025 - 2030 |
| Estimated Market Value ( USD | $ 2.35 Billion |
| Forecasted Market Value ( USD | $ 2.86 Billion |
| Compound Annual Growth Rate | 4.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
